[en] BACKGROUND: Hypertransfusion with a baseline hemoglobin of 10 to 12 g per dL is still considered by many to be the mainstay of conservative therapy for beta-thalassemia major. However, this regimen is frequently associated with manifestations of transfusion iron overload, despite regular chelation therapy with subcutaneous desferoxamine. STUDY DESIGN AND METHODS: To verify whether a transfusion regimen with a target pretransfusion hemoglobin level between 9 and 10 g per dL can allow a significant reduction in blood consumption, while still effectively suppressing erythropoiesis, the records were reviewed of 32 beta-thalassemia major patients, who were maintained at a pretransfusion hemoglobin of 11.3 +/- 0.5 g per dL between 1981 and 1986. These patients were switched at the beginning of 1987 to a transfusion regimen with pretransfusion hemoglobin of 9.4 +/- 0.4 g per dL. The degree of erythroid marrow activity was evaluated in these patients and in 32 subjects with beta-thalassemia intermedia through the simple measurement of serum transferrin receptor. RESULTS: After the adoption of the moderate transfusion regimen, transfusion requirements decreased from 137 +/- 26 to 104 +/- 23 mL per kg per year of red cells (p < 0.0001), and mean serum ferritin decreased from 2448 +/- 1515 to 1187 +/- 816 micrograms per L (p < 0.0001), with one-half of patients achieving serum ferritin levels lower than 1000 micrograms per L. The proportion of patients having spontaneous pubertal development increased significantly (p < 0.01), as a result of less iron-related gonadotropin insufficiency. At the lower pretransfusion hemoglobin, erythroid marrow activity did not exceed two to three times normal levels in most subjects. CONCLUSION: As compared with hypertransfusion, moderate transfusion may allow more effective prevention of iron loading, with higher likelihood of spontaneous pubertal development and without producing excessive expansion of erythropoiesis.
Disciplines :
Hematology
Author, co-author :
Cazzola, M.
Borgna-Pignatti, C.
Locatelli, F.
Ponchio, L.
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
De Stefano, P.
Language :
English
Title :
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
Publication date :
1997
Journal title :
Transfusion
ISSN :
0041-1132
eISSN :
1537-2995
Publisher :
American Association of Blood Banks, Bethesda, United States - Maryland
Piomelli S, Karpatkin MH, Arzanian M, et al. Hypertransfusion regimen in patients with Cooley's anemia. Ann N Y Acad Sci 1974;232:186-92.
Propper RD, Button LN, Nathan DG. New approaches to the transfusion management of thalassemia. Blood 1980;55:55-60.
Beguin Y, Clemons GK, Pootrakul P, Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993;81:1067-76.
Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Colleycare Programme. Lancet 1991;337:277-80.
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
Piomelli S. The management of patients with Cooley's anemia: transfusions and splenectomy. Semin Hematol 1995;32:262-8.
Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in β-thalassaemia intermedia. Lancet 1979;2:819-21.
Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood 1988;71:1124-9.
Pootrakul P, Hungsprenges S, Fucharoen S, et al. Relation between erythropoiesis and bone metabolism in thalassemia. N Engl J Med 1981;304:1470-3.
Pippard MJ, Rajagopalan B, Callender ST, Weatherall DJ. Iron loading, chronic anemia, and erythroid hyperplasia as determinants of the clinical features of β-thalassemia intermedia. In: Weatherall DJ, Fiorelli G, Gorini S, eds. Advances in red blood cell biology. New York: Raven Press, 1982:63-70.
Cazzola M, De Stefano P, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in β-thalassemia major. Br J Hematol 1995:89:471-8.
Cazzola M, Pootrakul P, Bergamaschi G, et al. Adequacy of iron supply for erythropoiesis: in vivo observations in humans. J Lab Clin Med 1987;110:734-9.
Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood 1982;60:288-94.
Cazzola M, Ascari E, Barosi G, et al. Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet 1983;65:149-54.
Bronspiegel-Weintrob N, Olivieri NF, Tyler B, et al. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990;323:713-9.